Abbott has launched its Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease at the European Society of Cardiology (ESC) Congress this week in Barcelona, Spain.
Xience Prime, which received CE Mark approval in June, is now available in Europe, and in select countries in Asia-Pacific and Latin America.
According to the Abbott Park, Ill.-based company, Xience Prime utilizes the same drug and biocompatible polymer as its Xience V everolimus-eluting coronary stent system. The new drug-eluting stent also is based on the design used in the Multi-Link Vision family of stents. Xience Prime uses cobalt chromium technology. Xience Prime is available in a various size matrix, including Xience Prime SV for small vessels and Xience Prime LL for long lesions.
Xience Prime currently is an investigational device in the United States and is not available for sale in that country.